Artificial neural network-based pharmacogenomic algorithm for warfarin dose optimization

To develop more precise pharmacogenomic algorithm for prediction of safe and effective dose of warfarin. An artificial neural network (ANN) algorithm was developed by using age, gender, BMI, plasma vitamin K levels, thyroid status and ten genetic variables as the inputs and therapeutic warfarin dose...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacogenomics 2016-01, Vol.17 (2), p.121-131
Hauptverfasser: Pavani, Addepalli, Naushad, Shaik Mohammad, Kumar, Rajasekar Manoj, Srinath, Murali, Malempati, Amaresh Rao, Kutala, Vijay Kumar
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To develop more precise pharmacogenomic algorithm for prediction of safe and effective dose of warfarin. An artificial neural network (ANN) algorithm was developed by using age, gender, BMI, plasma vitamin K levels, thyroid status and ten genetic variables as the inputs and therapeutic warfarin dose as the output. Hyperbolic tangent function was used to build an ANN architecture. This model explained 93.5% variability in warfarin dosing and predicted warfarin dose accurately in 74.5% patients whose international normalized ratio (INR) was less than 2.0 and in 83.3% patients whose INR was more than 3.5. This algorithm reduced the out-of-range INRs (odds ratio [OR]: 0.49; 95% CI: 0.30-0.79; p = 0.003), the rate of adverse drug reactions (OR: 0.00; 95% CI: 0.00-1.21; p = 0.06) and time to reach first therapeutic INR (OR: 6.73; 95% CI: 2.17-22.31; p < 0.0001). This algorithm was found to be applicable in both euthyroid and hypothyroid status. S-warfarin/7-hydroxywarfarin ratio was found to increase in subjects with and justifying the warfarin sensitivity attributed to these variants. An application of ANN for warfarin dosing improves predictability and provides safe and effective dosing.
ISSN:1462-2416
1744-8042
DOI:10.2217/pgs.15.161